Dengue lgG ELISA,specification,price,image-Bio-Equip in China

Product Detail
Company Profile

For in vitro diagnostic and professional use only.

INTENDED USE 96TESTS/KIT
The Dengue lgG ELISA is for the qualitative detection of lgG antibodies to dengue antigen serotypes (1, 2, 3 and4) in serum or plasma, as an aid in the clinical laboratory diagnosis of patients with clinical symptoms and past exposure consistent with dengue fever. It mayalso be used todistinguish between primary and secondarydengue infection. PRINCIPLE This kit utilizes the indirect ELISA (Enzyme-Linked Immunosorbent Assay) principle to detect IgG antibodies against dengue virus in human serum. The microplate strips are pre-coated with recombinant dengue virus antigens that bind to the relevant antibodies in the samples. The specimens to be tested are added and incubated, a lowing the IgG antibodies in the specimens to bind to the antigens. The plate is then washed to remove any substances that do not bind to the coated antigens. Enzyme-labeled reagents are added for a second incubation. When IgG antibodies against dengue virus are present in the sample, a "coated antigen-IgG antibody-anti-human IgG enzyme conjugate" complex is formed. After washing the plate again, a chromogenic substrate is added. The HRP (Horseradish Peroxidase) attached to the complex catalyzes the reaction of the chromogenic substrate, generating a colored product. Upon termination of the reaction, a yellow color develops. If there are no IgG antibodies against dengue virus in the sample, no color wi l develop. The OD (Optical Density) value is measured using an ELISA reader or an immunoassaysystem,and thepresenceofIgG antibodiesagainst dengue virus isdetermined based on the OD value. SUMMARY Dengue fever(DF) and dengue hemorrhagic fever (DHF) are caused by one of 4 serotypes of the virus of the genus Flavivirus that although closely related are antigenically distinct (DEN-1, DEN-2, DEN-3, and DEN-4). DF and DHF are diseases of mainly tropical and subtropical areas. The 4 dengue serotypes are maintained in a cycle involving humans and the Aedes mosquito. Infections produce a spectrum of clinical disease ranging from nonspecific viral syndrome to severe and fatal bleeding disease. Clinical manifestations include rash, sudden onset of fever, chills, severe headache, nausea, myalgia and arthralgia, leukopenia, thrombocytopenia and haemorrhagic manifestations. Occasionally it produces shock and hemorrhage causing death. An important risk factor for DHF is the strain of virus that causes the infection, as we l as the patient's age andespecia ly the history of previous dengue infections. Dengue viremia appears to be universal in febrile dengue patients; It occurs prior to the onset of fever and symptoms and has a peak 2-3 days after the onset of the disease. A diagnosis of acute infection with dengue virus can be made by isolating the virus or by detection of the viral genome or antigen. Serologically, a primary dengue infection results in detectable levels of IgM antibodies by the third day of infection without fever. These IgM antibodies persist for 1-2 months after infection. IgG antibodies are detected approximately 14 days after the onset of primary infection. Secondary infections with dengue virus are characterized by a rapid increase in IgG antibody levels. Due to the relatively late increase in antibody levels to a diagnostica ly detectable concentration, a negative result of an antibody detection test early in the course of the disease is not definitive. Samples should be collected at least 7 days after the onsetof symptoms to exclude thepossibility of acute dengue virus infection. Serology is the most widely used technique in routine diagnosis. Traditionally, hemagglutination inhibition and virus neutralization tests have been used. ELISAs for IgM and IgG antibodies are the standards for serological analysis of denguevirus infections, as they are simple anda low testing of a large number of samples